Sarepta Therapeutics (SRPT) Could Be 22% Undervalued Following SRP 1003 Preclinical Data

Sarepta Therapeutics (SRPT) just put fresh preclinical data for its SRP-1003 program in front of specialists, showing up to roughly 80% knockdown of pathogenic DMPK RNA in myotonic dystrophy type 1 models.

That fresh Sarepta Therapeutics update landed against a tougher share price backdrop, with the stock at US$16.83 after a 30 day share price return that is down 19.6% and a year to date share price move that is down 21.0% as investors reassess both growth prospects and risk. Over a longer stretch, total shareholder return has fallen 24.2% over one year and 85.2% over three years, so any new clinical data like SRP-1003 tends to be viewed through a lens of rebuilding confidence rather than riding strong momentum.

Scan beyond Sarepta Therapeutics and consider other rare-disease and high-science opportunities using our hand picked 34 healthcare AI stocks, which could reward patience when sentiment turns back to clinical progress.

After that kind of drawdown, Sarepta Therapeutics at US$16.83 screens far below many fair value estimates. Is the market roughly right or is the gap to analyst targets too wide to ignore?

Most Popular Narrative: 22% Undervalued

On the most followed view, Sarepta Therapeutics screens well below an estimated fair value of $21.73, even after the recent drawdown to $16.83. That gap rests less on short term trading and more on how durable the Duchenne franchise and newer RNA programs prove to be.

Sarepta Therapeutics is using a cash flow positive Duchenne muscular dystrophy portfolio, with Q2 2026 product gross margins of 75% and non GAAP operating income of US$86 million, to self fund pipeline work and potentially support future earnings and cash generation without relying on new equity.

See why 42 investors see Sarepta Therapeutics as 23% undervalued.

Result: Fair Value of $21.73 (UNDERVALUED)

Still, this Sarepta Therapeutics thesis leans heavily on cleaner ELEVIDYS safety data and smoother infusion logistics, where any setback could quickly challenge that undervalued story.

Find out about the key risks to this Sarepta Therapeutics narrative.

Next Steps

If this combination of pressure and potential around Sarepta Therapeutics feels familiar, use it as a prompt to look directly at the underlying numbers, risks and pipeline yourself. Then weigh that against the upside narrative through 2 key rewards and 1 important warning sign.

Looking for more Sarepta Therapeutics sized ideas?

Do not stop with Sarepta Therapeutics. Use this as a spark to widen your watchlist and line up the next set of opportunities before everyone else notices.

• Target potential mispricings by scanning companies that combine quality fundamentals with attractive valuations through the 32 high quality undervalued stocks.
• Build a steadier income stream by focusing on businesses that offer robust yields using the 7 dividend fortresses.
• Protect your capital by concentrating on financially resilient businesses screened through the 32 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com